Eighty-Third Edition of the Global Health Cast presented by Prof. Schmitt and Dr. Sanicas. Download PDF here 🔒 Premium Content - For FreeUnlock this content by becoming a Global Health Press subscriber. Join for...
Eighty-Second Edition of the Global Health Cast presented by Prof. Schmitt and Dr. Sanicas. Download PDF here🔒 Premium Content - For FreeUnlock this content by becoming a Global Health Press subscriber. Join for...
Scientists investigating animal viruses with potential to infect humans have identified a critical protein that could enable spillover of a family of organisms called arteriviruses. In a new study, researchers...
The Democratic Republic of the Congo (DRC) has reached a major public health milestone by successfully integrating the malaria vaccine into its national routine immunization programme. This remarkable initiative has...
Investigators led by Pablo Penaloza-MacMaster, PhD, associate professor of Microbiology-Immunology, have discovered that administering an antibody treatment four days after mRNA vaccination enhances immune responses and...
Scientists at the Icahn School of Medicine at Mount Sinai have developed a novel antibody platform called the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform, designed to counteract viral...
Imagine living in a world where a simple infection could be life-threatening because no antibiotics work. This is the looming threat of antimicrobial resistance (AMR), and it’s a reality that many young people today are...
Scientists at Delft University of Technology have discovered that our immune system uses Guanylate Binding Proteins (GBPs) to fight off bacterial infections by forming a destructive coat around bacteria. This research...
A new mRNA-based vaccine offers significant promise in both treating and preventing the highly contagious and notoriously difficult-to-treat Clostridioides difficile (C. difficile) infection, also known as C. diff. In...
The value of mRNA licensing agreements has skyrocketed by a staggering 800% between 2019 and 2024, driven by the success of mRNA-based COVID-19 vaccines and growing confidence in the technology’s broader...